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What cardiologists need to know 
about cardiovascular magnetic 
resonance (CMR)
acquire and interpret the scan. CMR is an interactive process that 
doesn’t just require the operator to simply “push a button”. 
Clinical scans are acquired on a 1.5 or 3 Tesla machine. Surprisingly 
the stronger field strength does not always provide superior cardiac 
imaging due to a number of specific artifacts at 3T.(2)  Most scans 
generally take 20 - 40 minutes to complete although more complex 
cases such as adult congenital imaging can take up to 1 hour. The 
patient therefore has to be able to tolerate lying supine, generally, 
for this period of time without a break – which can be problematic 
in patients with decompensated heart failure. 
Images are acquired during breath-holds of 10 - 15 seconds. The 
image is formed from data collected over consecutive heartbeats 
and mis-registration occurs if the heart is moving with respiration. 
Similar artifacts occur with arrhythmias which can render a scan 
non-diagnostic. Controlled atrial fibrillation and low frequency 
ectopy are manageable, high frequency ectopy can however cause 
major problems. Pharmacological control of the arrhythmia should 
be considered prior to imaging (e.g. beta blockers).
Anatomic spin-echo images are acquired first in the traditional 
anatomic planes. Standard sets of functional (cine) images are then 
acquired following prescribed rules. These include vertical and 
horizontal long axis (2chamber/4ch), LVOT and a short axis stack. 
Additional cines are acquired as needed which can include 
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Although considered by many to be a novel imaging technique 
CMR has been in clinical use for over 15 years and is part of routine 
cardiology practice in many countries. The “novelty” seems to 
come from lack of availability and therefore experience with the 
modality. This article aims to provide an explanation of how clinical 
cardiac MRI fits into the diagnostic armoury of the clinical 
cardiologist. 
The commonly expressed benefits of CMR include terms such as 
“non-invasive”, “non-ionising” and “safe”; however there are much 
more robust reasons to be mentioned. CMR often makes the 
diagnosis where other tests would fail mainly due its unique ability 
to characterise myocardial tissue but also due to the clarity of 
functional imaging.(1) MR has significantly advanced our understanding 
of cardiac pathology and yielded new insights into management and 
prognosis.
HOW A CMR IS EXECUTED
CMR not only requires a magnet with appropriate cardiac software, 
but highly trained technicians, cardiologists and radiologists to 
Cardiovascular Magnetic Resonance (CMR) is increasingly 
used in the evaluation of patients with cardiac and aortic 
disease. The ability to characterise myocardial tissue, 
function and anatomy (in any plane) without any exposure 
to ionising radiation are the main advantages over other 
imaging modalities used in cardiology. In this article we 
discuss the principles underlying the imaging technique, 
safety issues, indications and strengths of CMR. It aims to 
provide a concise, practical overview for the general cardi-



















dedicated images of the right heart, pulmonary arteries and aorta. 
Tissue characterisation images are subsequently acquired in the 
same planes. These can include sequences to highlight water and 
thus tissue oedema (T2 weighted-STIR images), myocardial iron 
(T2*) and focal fibrosis (late gadolinium, inversion recovery imag-
ing) as needed. Following the scan, the short axis stack is analysed 
with semi-automated, border detection software to give highly 
reproducible measurements of ventricular volumes and function.(3-6)
Chelated gadolinium-based contrast agents are used to charac-
terise the myocardium and often for MR angiography. These agents 
do not contain iodinated material and are not contra-indicated in 
patients with previous reactions to radio-opaque contrast agents. 
Gadolinium-based contrast agents are generally well tolerated with 
1-5% patients experiencing minor nausea and transient headache. 
Allergic reactions are rare and are reported to occur in every 
10 000 - 50 000 patients. A number of cases of nephrogenic 
systemic fibrosis (NSF) have now been reported in patients with 
end-stage renal failure receiving linear gadolinium agents.(7-9) NSF is 
much less likely with the newer cyclical compounds however, 
gadolinium administration is relatively contra-indicated in patients 
with impaired renal function and should be considered contra-
indicated in patients with severe kidney disease. That said, it is 
generally considered reasonable to administer cyclical gadolinium 
agents in patients with a GFR greater than 30ml/min if clinically 
indicated. Dialysis has not yet been proven to prevent NSF but 
can aid clearance of Gd-DTPA.(9)
Gadolinium is taken up from the blood pool into the interstitium of 
tissue. The myocardial interstitial space is increased in areas of 
inflammation, infiltration and fibrosis. Gadolinium alters the T1 
relaxation time of these areas thereby altering the signal obtained 
relative to the normal myocardium. These areas appear white 
(hyper-enhanced) as opposed to normal black (nulled) myocardium. 
Different patterns of hyper-enhancement suggest different patho-
logies; for instance, myocardial infarction is seen beginning from 
the sub-endocardium however the distribution of hyper-enhance-
ment in myocarditis is mid-wall or sub-epicardial.(10)
SAFETY AND CONTRA-INDICATIONS
As a MR system consists of a large, static magnetic field in which 
radiofrequency (RF) energy is periodically released during imaging, 
there are possible hazards associated with its use. In general, the 
potential hazard of implants or devices is dependent on factors 
such as its degree of ferromagnetism, geometry, location in the 
body as well as the gradient and field strength of the imaging 
magnet. In assessing whether a particular patient should be 
subjected to a CMR scan, the main rule, as with other investigations 
in medicine, is to determine the risk-benefit ratio to the patient of 
the proposed study. 
It is absolutely essential to carefully interview the patient prior to 
a MRI examination, and most centres would require a safety 
questionnaire to be completed. Whenever there is a concern 
about the safety of a patient with an implant, the CMR examination 
should be deferred until the device and the issues associated with 
it are clarified. Reference texts [Shellock FG. Guide to MR 
Procedures and Metallic Objects: Update 2001, 7th edition. 
Philadelphia: Lippincott, Williams and Wilkins Healthcare, 2001] 
and web-based information (www.MRIsafety.com) on the safety of 
specific devices are available.
Pacemakers remain a contra-indication to cardiac MR currently, 
however most loop recorders are considered safe at 1.5T. Patients 
with prosthetic heart valves and coronary stents (as early as 
24 hour after implantation) can be safely imaged at 1.5T.(11,12) 
Some image degradation can occur with prosthetic material due 
to local disruption of the magnetic field.
Most, if not all orthopaedic implants, are safe. However, loose, 
metallic foreign bodies, cochlear implants and intracranial aneurysm 
clips are considered a strong contra-indication to MRI.
Newer MRI machines have larger bores however, claustrophobia 
can still be a problem. Minor degrees of anxiety can be overcome 
utilising blindfolds, prism spectacles or scanning prone. Sedation is 
generally avoided as patient cooperation is required although 
general anaesthesia can be used in specific circumstances.
WHEN AND WHY SHOULD CMR BE 
CONDUCTED?
The incremental value of CMR above echocardiography lies in the 
ability to characterise myocardial tissue and image the heart 
unencumbered by other thoracic structures eg ribs, lungs. Pre-
scribed imaging plans eliminate foreshortening and ensure accurate 
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cross-sectional measurement. The ability to clearly image the apex 
is obviously important when looking for mural thrombus or apical 
hypertrophic cardiomyopathy.(13) Although, a detailed review of 
each CMR indication is outside the scope of this article, the major 
current clinical uses are described in brief.
Tissue characterisation in heart failure
A major indication for CMR is to clarify the aetiology of heart 
failure. The formerly used gadolinium enhancement CMR tech-
nique (LGE-CMR) has potential roles in both diagnosis and prog-
nosis of newly diagnosed heart failure patients. Specific patterns of 
fibrosis and scarring have been identified in many of the cardio-
myopathy states(14,15) and are summarised in Figure 1. Ischaemic 
cardiomyopathy is characterised by sub-endocardial-based areas 
of late enhancement that correlate to irreversible myocardial 
necrosis on histopathology (Figure 2), a pattern consistent with 
the ‘‘wave front phenomenon’’ as described by Reimer and col-
leagues.(16) Patients who have non-ischaemic dilated cardiomyo-
pathy may also have LGE-CMR evidence of scarring in up to 30% 
of cases; however, this is typically in a non-coronary distribution 
and frequently appears as a mid-wall striate.(14) Therefore, based 
on the presence and pattern of myocardial fibrosis, the aetiology 
of the cardiomyopathy can be accurately ascertained. Delineation 
of the underlying aetiology is of clinical value for patients with heart 
failure. In patients with ischaemic substrate causing their heart 
failure, the delineation of potential areas of myocardial ischaemia 
and viability is crucial to defining clinical management. In non-
ischaemic cardiomyopathy, extensive mid-wall fibrosis at pre-
sentation of symptoms, is indicative of a worse prognosis and a 
poorer response to standard heart failure therapy.(17) Other 
conditions such as cardiac amyloidosis, sarcoidosis and endomyo-
cardial fibrosis all have classical patterns of late gadolinium hyper-
enhancement (see Figure 3).
Left ventricular hypertrophy (LVH) diagnosed by ECG, echo or 
chest radiography can be formally assessed by CMR especially in 
the absence of an obvious cause such as hypertension or obstructive 
aortic valve disease. A number of conditions can masquerade as 
phenocopies of hypertensive LVH including hypertrophic cardio-
myopathy, amyloidosis and cardiac tumours.
Myocardial viability
Two CMR techniques are currently used for the assessment of 
myocardial viability:
 ■ Late Gadolinium Enhancement CMR (LGE-CMR), a technique 
unique to CMR, that defines the transmural extent of scar, and 
 ■ Dobutamine CMR analogous to Dobutamine echocardiography 
that measures the contractile reserve of dysfunctional myo-
cardium and is interpreted by visual analysis. 
In the setting of chronic ischaemic cardiomyopathy, a number of 
clinical studies have examined whether the transmurality of the 
myocardial infarction can predict recovery of contractile function. 
Essentially, these studies found that the likelihood of improve-
ment in regional function after revascularisation decreased progres-
sively as the transmural extent of LGE before revascularisation 
increased.(18) This assessment is generally used to guide revascu-
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FIGURE 1: Hyperenhancement patterns seen on Late 
Gadolinium CMR imaging.
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FIGURE 2: CMR in acute myocardial infarction.
Early and Late gadolinium imaging in the peri-infarct period. A, B & C demonstrate microvascular obstruction (thin arrows) in anteroseptal and apical 





FIGURE 3: CMR in various Cardiomyopathies.
A. Takostubo Cardiomyopathy.T2-STIR imaging demonstrating increased signal intensity in mid to apical (arrows) LV indicating oedema. B. Cardiac 
Sarcoid. Patchy sub-epicardial hyperenhancement (arrows) in short axis view on late gadolinium imaging. C. Cardiac Amyloid. Global sub-endocardial 
hyperenhancement (arrows) of LV and RV in short axis view on late gadolinium imaging.
A B C
larisation, but can also be used to plan resynchronisation therapy 
(“dead meat don’t beat” i.e. one cannot pace non-viable scarred 
myocardium). 
One of the key determinants of prognosis in ischaemic LV 
dysfunction is left ventricular end-diastolic volume and ejection 
fraction (EF). Kim, et al. utilising LGE-CMR,(19) and Rizello, et al. 
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employing DSE,(20) have shown a linear relationship between the 
number of viable segments pre-revascularisation and change in 
LVEF post-revascularisation. Pegg, et al. have recently elegantly 
demonstrated that the sum of normal plus viable segments of 
greater than 10 on a 16 segment AHA model will accurately predict 
increase in LV ejection fraction.(21) 
Fifty patients underwent CMR to assess LV function and viability 
before and 6 months after CABG. Viability was defined as trans-
mural hyper-enhancement of <50% (i.e. a binary variable) and the 
presence of 10 or more viable or normal segments predicted a 
gain of 3% in LVEF with a sensitivity and specificity of 95% and 
75% respectively. Assessment of scar using LGE is undisputed in 
patients with either no LGE or >75% transmurality. However, in 
intermediate transmural segments (25 to 75%), low dose dobu-
tamine to assess contractile reserve is considered superior to scar 
quantification.(22) 
Kuhl, et al. studied 26 patients with ischaemic cardiomyopathy, 
with SPECT,(18) F-flurodeoxyglucose Positron Emission Tomo-
graphy (FDG PET) and LGE-CMR. LE-CMR was able to differentiate 
viable myocardium as defined by PET, with sensitivity of 96% and 
specificity of 84%. This study demonstrated that LGE-CMR is as 
good as FDG PET in the assessment of myocardial viability.(23) More 
recent literature shows that a combination of various CMR para-
meters such as wall thickness, scar quantification and contractile 
reserve are most efficient in predicting functional recovery.(24,25) 
Troponin positive chest pain
Patients frequently present with troponin positive chest pain and 
are subsequently found to have patent coronary arteries at 
angiography. Previously these patients would have been perma-
nently labelled as having had a myocardial infarction and treated 
as such. CMR has changed the paradigm of how these patients 
are managed. CMR performed during the acute presentation com-
monly reveals 3 possible aetiologies. 
Firstly, it can show that acute myocarditis (often with no clear viral 
prodrome clinically) is present. A combined CMR approach using 
T2-weighted imaging and contrast enhanced T1 weighted images, 
provides high diagnostic accuracy and is a useful tool in the diag-
nosis and assessment of patients with suspected acute myo-
carditis.(26) LGE in the setting of myocarditis has a “non-ischaemic” 
pattern, typically affecting the sub-epicardium and the mid-myo-
cardial wall. This focal hyper-enhancement becomes diffuse over a 
period of days to weeks, then decreases during healing and may 
become invisible after recovery. Occasionally, the CMR reveals the 
diagnosis to be acute myocardial infarction even with relatively 
normal coronary arteries at angiography. Thirdly, CMR can show/
confirm the diagnosis of Stress (Takotsubo) cardiomyopathy.(27) 
The characteristic patterns of oedema settle quickly in the above 
conditions and prompt imaging is recommended to increase 
diagnostic yield. Achieving an accurate diagnosis has obvious 
benefits for future management and life/health insurance purposes.
Adult congenital heart disease
Due to the flexibility and quality of the images obtainable, CMR 
is particularly well suited to imaging congenital heart disease. 
These patients often have poor echo windows and the right 
heart is notoriously difficult to assess fully. Serial follow up of great 
vessels and right heart dimensions is important when planning 
operative intervention and an accurate, non-ionising modality such 
as CMR is clearly preferable. Optimal visualisation of the right 
heart is important in the increasing recognised entity of arrhyth-
mogenic right ventricular cardiomyopathy when wall motion and 
chamber size are part of the diagnostic criteria set out by ARVC 
Task Force.(28)
Ischaemia assessment
A significant percentage of CMR studies are dedicated to ischaemia 
testing. However, administration of dobutamine is suboptimal for 
patient comfort and care in the MR environment. The real 
advantage lies in first-pass myocardial perfusion imaging under 
vasodilator stress. Here, a bolus of gadolinium-based contrast agent 
is injected into a peripheral vein and a sequence of images is then 
obtained to follow the dynamic passage of dye through the heart. 
Vasodilatation with adenosine or dipyridamole induces an increase 
in blood flow (hyperaemia) in myocardial areas subtended by 
normal coronary arteries, whereas no or only minimal changes are 
found in areas supplied by stenotic coronary arteries. This relative 
hypo-enhancement in under perfused areas is usually evident 
visually and constitutes a perfusion defect (Figure 4). 


















In a large, prospective study, Greenwood, et al. very elegantly 
demonstrated the superiority and high diagnostic accuracy of 
CMR over SPECT in the detection of coronary heart disease.(29) 
They studied 752 patients with suspected coronary heart disease 
with multi-parametric CMR and Single-Photon Emission Computed 
Tomography (SPECT). X-ray coronary angiography was the 
reference standard. Multi-parametric CMR had a sensitivity of 
86.5% (vs 66%), specificity of 83% (vs 82%) and negative predictive 
value of 90.5% (vs 79%). Several single-centre studies and a 
published multicentre trial have compared perfusion CMR favour-
ably (sensitivities >90%, specificity around 80 - 85%) to existing 
nuclear methods (SPECT) or invasive cardiac catheterisation for 
the detection of myocardial ischaemia in the setting of chronic 
chest pain.(30) A negative CMR perfusion in patients presenting 
with chest pain without ECG changes or cardiac biomarker 
abnormality, have an excellent short to mid term prognosis.(31)
WHEN SHOULD CMR NOT BE USED?
CMR is not the panacea for all cardiac imaging requirements. Whilst 
perfusion imaging can quantify myocardial blood flow, a reliable, 
quick and robust luminographic assessment of the entire coronary 
arteries is not yet possible on most clinical systems. High-volume 
centres with appropriate skills can reliably image the proximal 
course of the coronary arteries to exclude anomalous coronary 
anatomy obviating the need for CT and the associated radiation.
The temporal resolution of CMR is currently limited which reduces 
the ability to detect small hypermobile structures such as vege-
tations. The sequelae of endocarditis such as root abscesses can 
be assessed however.(32) 
Echocardiography remains supreme in the evaluation of valvular 
lesions however CMR can complement echo in cases where the 
degree of severity is unclear such as aortic regurgitation. Volumetric 
differences can be used to calculate regurgitant fractions in isolated 
valvular lesions and in combination with flow measurements in 
more complex cases. The same techniques can be used to assess 
shunting in congenital heart disease.
Finally, the multiple facets of CMR make the modality invaluable in 
the assessment of pericardial pathology and cardiac masses. 
Tumours can be reliably distinguished from other masses such as 
thrombus and often the type of tumour can be revealed by tissue 
characterisation sequences.(33)
CONCLUSION
Cardiac magnetic resonance imaging is a powerful clinical tool 
enabling cardiologists to accurately differentiate and diagnose 
cardiac pathology. CMR technology and applications continue to 
rapidly advance with positive implications for interventional cardi-
ology and clinical research too. Useful resources for further reading 
can be found at www.scmr.org. The website has a vast and 
fascinating clinical case archive which will illustrate much of this 
article. 
Conflict of interest: none declared.
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FIGURE 4: CMR-Stress perfusion imaging.
Perfusion defect in the inferior segment (arrow).
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